Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-290 and Temozolomide in AYA IDH1/2 Mutant Gliomas
NCT03749187Phase 1Active, not recruiting
- Sponsor
- University of California, San Francisco
- Start
- Apr 2019
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pamiparib in glioma (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Apr 2019; status: active, not recruiting.
02
Drugs
pamiparib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03749187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03749187.